IP Library › Patent Application 12721244
Patent Application
App. No. 12/721,244

METHODS FOR TREATING BONE TUMORS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/721,244
Abstract

The present invention provides methods of treating bone cancer, inducing differentiation of bone tumor cells, inhibiting bone tumor growth, inducing bone tumor regression or treating a hyperproliferative cell disorder by administering a pharmaceutically effective amount of a bone morphogenic protein or a nucleic acid encoding the bone morphogenic protein.

Claims (11)

1 - 16 . (canceled)

17 . A method of treating a secondary bone cancer in a mammal comprising the step of administering to the mammal a pharmaceutically effective amount of OP-1 or a nucleic acid encoding OP-1.

18 . The method according to claim 17 , wherein the secondary bone cancer metastasized from breast, lung or prostate.

19 . A method of inducing regression of a secondary bone cancer in a mammal comprising the step of administering to the mammal a pharmaceutically effective amount of OP-1 or a nucleic acid encoding OP-1.

20 . The method according to claim 19 , wherein the secondary bone cancer metastasized from breast, lung or prostate.

21 . The method according to any one of claims 17 to 20 , wherein the nucleic acid is a viral vector comprising a gene that encodes OP-1, and wherein the viral vector is selected from the group consisting of an adenoviral vector, a lentiviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector and a herpes simplex viral vector.

22 . The method according to claim 21 , wherein the viral vector is selected from the group consisting of an adenoviral vector, a baculoviral vector and a lentiviral vector.

23 . The method according to claim 22 , wherein the viral vector is an adenoviral vector.

24 . The method according to any one of claims 17 to 20 , wherein OP-1 or the nucleic acid encoding OP-1 is formulated as a gel, an aqueous solution, a paste or a putty.

25 . The method according to claim 24 , wherein the formulation is a sustained release formulation.

26 . The method according to claim 24 , wherein OP-1 or the nucleic acid encoding OP-1 is formulated for local administration.